Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a higher price-to-earnings ratio of 26.48x compared to its average ratio. REGN has 36-month beta value of 0.15. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 7 as “overweight,” 12 as “hold,” and 1 as “sell.”
The public float for REGN is 105.09M, and currently, short sellers hold a 1.35% ratio of that float. The average trading volume of REGN on April 12, 2024 was 471.66K shares.
REGN) stock’s latest price update
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)’s stock price has plunge by -1.70relation to previous closing price of 936.20. Nevertheless, the company has seen a -1.78% plunge in its stock price over the last five trading sessions. Investopedia reported 2024-04-11 that Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare’s drug pricing reporting by inflating the average sales price of its best-selling eye disease drug Eylea.
REGN’s Market Performance
Regeneron Pharmaceuticals, Inc. (REGN) has experienced a -1.78% fall in stock performance for the past week, with a -5.18% drop in the past month, and a 1.56% rise in the past quarter. The volatility ratio for the week is 1.54%, and the volatility levels for the past 30 days are at 1.49% for REGN. The simple moving average for the last 20 days is -3.84% for REGN stock, with a simple moving average of 7.89% for the last 200 days.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Bernstein repeating the rating for REGN by listing it as a “Outperform.” The predicted price for REGN in the upcoming period, according to Bernstein is $1125 based on the research report published on March 12, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see REGN reach a price target of $1076, previously predicting the price at $884. The rating they have provided for REGN stocks is “Outperform” according to the report published on January 12th, 2024.
Deutsche Bank gave a rating of “Hold” to REGN, setting the target price at $800 in the report published on November 09th of the previous year.
REGN Trading at -4.03% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.81% of loss for the given period.
Volatility was left at 1.49%, however, over the last 30 days, the volatility rate increased by 1.54%, as shares sank -4.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.11% lower at present.
During the last 5 trading sessions, REGN fell by -1.78%, which changed the moving average for the period of 200-days by +17.33% in comparison to the 20-day moving average, which settled at $954.81. In addition, Regeneron Pharmaceuticals, Inc. saw 4.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 250 shares at the price of $964.73 back on Apr 01 ’24. After this action, McCourt Marion now owns 13,181 shares of Regeneron Pharmaceuticals, Inc., valued at $241,182 using the latest closing price.
RYAN ARTHUR F, the Director of Regeneron Pharmaceuticals, Inc., sale 100 shares at $962.53 during a trade that took place back on Apr 01 ’24, which means that RYAN ARTHUR F is holding 18,182 shares at $96,253 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.88 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc. stands at 0.3. The total capital return value is set at 0.14. Equity return is now at value 16.26, with 12.67 for asset returns.
Based on Regeneron Pharmaceuticals, Inc. (REGN), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 1.7. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 108.21.
Currently, EBITDA for the company is 5.13 billion with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 7.57. The receivables turnover for the company is 2.31for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.69.
Conclusion
To put it simply, Regeneron Pharmaceuticals, Inc. (REGN) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
